{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:45:26Z","timestamp":1790196326759,"version":"4.1.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriatic arthritis is a chronic inflammatory disease with skin and joint pathology as the dominant characteristics. Scientific evidence supports its systemic nature and relevant relationship with obesity, metabolic syndrome, and associated conditions. Metabolic syndrome and obesity share common signaling pathways with joint inflammation, reinforcing the idea that adipose tissue is a major contributor to disease development and severity. The adipose tissue is not a mere energy store but also an endocrine organ participating in the immune response. In the search for the best therapeutic strategy for a patient, we should appraise the adipose tissue as an endocrine and immune organ responsible for mild chronic inflammation. Today, our challenge is not only to achieve disease remission but to control the associated comorbidities as well. In light of the high prevalence of obesity in psoriatic arthritis patients and the importance of the adipose tissue in the development of chronic inflammation, we aimed to identify the most relevant articles in this regard published in English until June 2020 using the PubMed database. Search terms included psoriatic arthritis, in combination with metabolic syndrome, obesity, adipokines, cardiovascular disease, and treatment. This review summarizes the current evidence regarding the role of adipose tissue as an adipokine-secreting endocrine organ, discussing its influence on disease development and severity, and ultimately in meeting successful disease management.<\/jats:p>","DOI":"10.3389\/fimmu.2020.590749","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T10:22:04Z","timestamp":1612952524000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Sabrina","family":"Porta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Otero-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo A.","family":"K\u00f6lliker Frers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Kerzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Capani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(94)80024-3","article-title":"Natural history of psoriatic arthritis","volume":"8","author":"Gladman","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1740593","article-title":"Metabolic Syndrome and psoriatic arthritis: considerations for the clinician","volume":"16","author":"Caso","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646774","article-title":"Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage","volume":"47","author":"Raimondo","year":"2017","journal-title":"Eur J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.39458","article-title":"Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment","volume":"68","author":"Kehl","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110845","article-title":"The ClASsification for Psoriatic ARthritis (CASPAR) criteria\u2013a retrospective feasibility, sensitivity, and specificity study","volume":"39","author":"Tillett","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201632","article-title":"The link between obesity and psoriatic arthritis","volume":"71","author":"Ca\u00f1ete","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00139","article-title":"Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors","volume":"9","author":"Kolliker Frers","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","article-title":"Trends in incidence of adult-onset psoriasis over three decades: a population-based study","volume":"60","author":"Icen","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000455840","article-title":"Psoriasis and Obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in Psoriatic Arthritis","volume":"41","author":"Husni","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104394","article-title":"Psoriatic arthritis: From pathogenesis to pharmacologic management","volume":"148","author":"Talotta","year":"2019","journal-title":"Pharmacol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.38773","article-title":"ZAP-70 Genotype Disrupts the Relationship Between Microbiota and Host, Leading to Spondyloarthritis and Ileitis in SKG Mice","volume":"66","author":"Rehaume","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120233","article-title":"The synovio-entheseal complex and its role in tendon and capsular associated inflammation","volume":"89","author":"McGonagle","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22758","article-title":"The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115424","article-title":"Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis","volume":"9","author":"Dolcino","year":"2014","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23681.x","article-title":"Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study","volume":"125","author":"Naldi","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr425","article-title":"Psoriasis and atherosclerosis: two plaques, one syndrome","volume":"33","author":"Flammer","year":"2012","journal-title":"Eur Heart J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150629","article-title":"Psoriatic Disease: Clinical Staging","volume":"93","author":"Scarpa","year":"2015","journal-title":"J Rheumatol Suppl"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5613056","article-title":"Cardiorenal Involvement in Metabolic Syndrome Induced by Cola Drinking in Rats: Proinflammatory Cytokines and Impaired Antioxidative Protection","volume":"2016","author":"Otero-Losada","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijcme.2015.01.005","article-title":"Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation","volume":"6","author":"K\u00f6lliker Frers","year":"2015","journal-title":"IJC Metab Endocr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/714321","article-title":"Cardiovascular risk in patients with psoriatic arthritis","volume":"2012","author":"Zhu","year":"2012","journal-title":"Int J Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.09.001","article-title":"Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis","volume":"36","author":"Kimhi","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.22884","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez-Juanatey","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1031822","article-title":"Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies","volume":"47","author":"Di Minno","year":"2015","journal-title":"Ann Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18227","article-title":"Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis","volume":"182","author":"Green","year":"2020","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160532","article-title":"The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study","volume":"44","author":"Eder","year":"2017","journal-title":"J Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202325","article-title":"Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity","volume":"72","author":"Eder","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000721","article-title":"Increased Prevalence of Metabolic Syndrome and Adipocytokine Levels in a Psoriatic Arthritis Cohort","volume":"24","author":"Feld","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046740","article-title":"Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions","volume":"7","author":"Xue","year":"2012","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04619-w","article-title":"Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset \u201csine psoriasis\u201d","volume":"38","author":"Caso","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12444","article-title":"Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity","volume":"19","author":"Dikbas","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114207","article-title":"Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2017.953","article-title":"Effects of secukinumab on serum adipocytokines: preliminary data","volume":"69","author":"Fassio","year":"2017","journal-title":"Reumatismo"},{"key":"B44","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/annrheumdis-2018-214737","article-title":"Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis","volume":"78","author":"Chandran","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2019_010","article-title":"Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis","volume":"120","author":"Colak","year":"2019","journal-title":"Bratisl Lek Listy"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17700","article-title":"Plasma levels of tumour necrosis factor-\u03b1 and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis","volume":"181","author":"Johnson","year":"2019","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1201423","article-title":"Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1078","article-title":"Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study","volume":"149","author":"Paller","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201299","article-title":"Obesity and the risk of psoriatic arthritis: a population-based study","volume":"71","author":"Love","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201273","article-title":"Obesity and risk of incident psoriatic arthritis in US women","volume":"71","author":"Li","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B52","first-page":"2013","article-title":"Overweight\/obesity: overweight by country","volume":"2013","author":"Organization","year":"2008","journal-title":"Global Health Observatory Data Reposit"},{"key":"B53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1475-2840-12-57","article-title":"Metabolic disturbances and worsening of atherosclerotic lesions in ApoE-\/- mice after cola beverages drinking","volume":"12","author":"Otero-Losada","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.06.005","article-title":"An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome","volume":"13","author":"Kumari","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00339","article-title":"Neuroprotection Targeting Protein Misfolding on Chronic Cerebral Hypoperfusion in the Context of Metabolic Syndrome","volume":"12","author":"Herrera","year":"2018","journal-title":"Front Neurosci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(03)00132-9","article-title":"Do regional differences in adipocyte biology provide new pathophysiological insights","volume":"24","author":"Lafontan","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coph.2017.08.006","article-title":"Adipose tissue inflammation in obesity: a metabolic or immune response","volume":"37","author":"Stolarczyk","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/endo.138.2.5033","article-title":"Leptin activates neurons in ventrobasal hypothalamus and brainstem","volume":"138","author":"Elmquist","year":"1997","journal-title":"Endocrinology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.05.027","article-title":"Adipocyte lineages: tracing back the origins of fat","volume":"1842","author":"Sanchez-Gurmaches","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/jdv.13131","article-title":"Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy","volume":"29","author":"Pina","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1530\/JOE-18-0174","article-title":"Chemerin: a multifaceted adipokine involved in metabolic disorders","volume":"238","author":"Helfer","year":"2018","journal-title":"J Endocrinol"},{"key":"B62","article-title":"Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Miranda-Filloy","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12944-019-1115-3","article-title":"New insights into different adipokines in linking the pathophysiology of obesity and psoriasis","volume":"18","author":"Kong","year":"2019","journal-title":"Lipids Health Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1467-789X.2002.00056.x","article-title":"Obesity, haemostasis and the fibrinolytic system","volume":"3","author":"Mertens","year":"2002","journal-title":"Obes Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.37.26287","article-title":"Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1","volume":"274","author":"Xu","year":"1999","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-48382-5_18","article-title":"Adiponectin-Resistance in Obesity","volume":"960","author":"Engin","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B67","first-page":"596","article-title":"High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis","volume":"26","author":"Gonzalez-Gay","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00368","article-title":"Relationships between Adipose Tissue and Psoriasis, with or without Arthritis","volume":"5","author":"Toussirot","year":"2014","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-052110-115718","article-title":"Adipogenesis: from stem cell to adipocyte","volume":"81","author":"Tang","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.216","article-title":"Increased activity of interleukin-23\/interleukin-17 proinflammatory axis in obese women","volume":"33","author":"Sumarac-Dumanovic","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-014-0214-1","article-title":"Is serum Interleukin-17 associated with early atherosclerosis in obese patients","volume":"12","author":"Tarantino","year":"2014","journal-title":"J Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3634","article-title":"Marrow fat and bone\u2013new perspectives","volume":"98","author":"Fazeli","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1515\/hmbci-2016-0012","article-title":"Bone marrow adipose tissue as an endocrine organ: close to the bone","volume":"28","author":"Sulston","year":"2016","journal-title":"Horm Mol Biol Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.06.003","article-title":"Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction","volume":"20","author":"Cawthorn","year":"2014","journal-title":"Cell Metab"},{"key":"B75","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar4404","article-title":"Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"15","author":"Meyer","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150813","article-title":"Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis","volume":"70","author":"Giles","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/art.30449","article-title":"Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis","volume":"63","author":"Klein-Wieringa","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2007.12.008","article-title":"A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes","volume":"16","author":"Lago","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.27450","article-title":"Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts","volume":"62","author":"Kusunoki","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.4468","article-title":"The potential of adiponectin in driving arthritis","volume":"176","author":"Ehling","year":"2006","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0546-x","article-title":"Influence of serum folic acid levels on plasma homocysteine concentrations in patients with rheumatoid arthritis","volume":"26","author":"Tiftikci","year":"2006","journal-title":"Rheumatol Int"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190867","article-title":"Homocysteine and psoriasis","volume":"39","author":"Lin","year":"2019","journal-title":"Biosci Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.02.002","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/art.34335","article-title":"Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study","volume":"64","author":"Chen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor \u03b1 blockade in psoriatic arthritis: a cross-sectional study","volume":"69","author":"Seitz","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111391","article-title":"Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-\u03b1 Blockers","volume":"39","author":"Di Minno","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1363884","article-title":"Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders","volume":"17","author":"Balato","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01439.x","article-title":"Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment","volume":"24","author":"Renzo","year":"2011","journal-title":"Dermatologic Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190729","article-title":"Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis","volume":"47","author":"Palmou-Fontana","year":"2020","journal-title":"J Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000501990","article-title":"Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience","volume":"11","author":"Tiberio","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04663-6","article-title":"Psoriatic arthritis and obesity: the role of anti-IL-12\/IL-23 treatment","volume":"38","author":"Costa","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12814","article-title":"Anti-TNF-\u03b1 therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study","volume":"29","author":"Pina","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13005","article-title":"Anti-TNF-\u03b1 therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study","volume":"30","author":"Pina","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217251","article-title":"Secukinumab efficacy in patients with PsA is not dependent on patients\u2019 body mass index","author":"Pantano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016400","article-title":"Obesity in psoriatic arthritis: Comparative prevalence and associated factors","volume":"98","author":"Queiro","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12235","article-title":"Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br J Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22645","article-title":"Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000751","article-title":"Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab","volume":"24","author":"Queiro","year":"2018","journal-title":"JCR: J Clin Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1162","article-title":"Early-onset obesity and risk for psoriatic arthritis","volume":"304","author":"Gladman","year":"2010","journal-title":"JAMA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.590749\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T10:22:16Z","timestamp":1612952536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.590749\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":111,"alternative-id":["10.3389\/fimmu.2020.590749"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.590749","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"article-number":"590749"}}